BiotechTube
Home/Lyra Therapeutics/Catherine Turkel, CPA
CT

Catherine Turkel, CPA

Chief Financial Officer

Lyra Therapeutics

Therapeutic Areas

Ear, Nose, and Throat (ENT)Inflammatory Diseases

Lyra Therapeutics Pipeline

DrugIndicationPhase
LYR-210Chronic Rhinosinusitis (CRS)Phase 3
LYR-220Chronic Rhinosinusitis (CRS)Not Specified (Pipeline)

Leadership Team at Lyra Therapeutics

MP
Maria Palasis, Ph.D.
President, Chief Executive Officer, and Director
DD
David Davidson, M.D.
Chief Medical Officer
RN
Richard Nieman, M.D.
Senior Vice President of Clinical Development
View full Lyra Therapeutics profile